Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Illumina Ventures
BioCentury | Jan 15, 2025
Emerging Company Profile
Mursla: Using extracellular vesicles to detect cancer
Led by former banker Pierre Arsène, the start-up’s first goal is surveillance of cirrhosis patients at risk of liver cancer
BioCentury | May 9, 2024
Finance
Venture report: Big rounds for Bluejay, Attovia and Zenas
Strong fundraising week also included launches by Prologue and Commit, plus raises by Aardvark, Memo and OverT
BioCentury | Oct 19, 2023
Regulation
Oct. 18 Quick Takes: FDA approves UCB’s Bimzelx and Zilbrysq
Plus: After appeal, Ardelyx wins approval of kidney therapy, and updates from Mablink, Actym, Syncona, CDER and more
BioCentury | Oct 6, 2023
Regulation
Oct. 5 Quick Takes: FDA panel declines to back Lumakras
Plus: Mirati rises after Sanofi takeout rumor circulates, ODAC panel and updates from Kyowa Kirin, AbbVie, Evotec, FDA, Precede and more
BioCentury | Oct 5, 2023
Regulation
Oct. 4 Quick Takes: FDA’s ODAC backs US WorldMeds’ eflornithine for neuroblastoma
Plus: ClavystBio launches space for start-ups in Singapore and updates from Novavax, Iambic, Sandoz, Shorla and more
BioCentury | Sep 19, 2023
Product Development
Sept. 18 Quick Takes: Anthos’ mAb meets Phase II bleeding endpoint
Plus: Priority review for Orchard’s ex vivo gene therapy and more from BioNTech, Broken String and FDA
BioCentury | Aug 18, 2023
Finance
Aug. 17 Quick Takes: China tools play Sangon attracts Novo Holdings in $290M round
Plus: Appeals court restricts mifepristone access and updates for Lightcast, AbbVie, Regeneron, Selecta, the IRA
BioCentury | Jun 21, 2023
Emerging Company Profile
Attovia: improving affinity and specificity using linked nanobodies
Alamar spinout Attovia is linking single heavy chain antibody pairs to double down on difficult therapeutic targets for cancer and immune diseases
BioCentury | Jun 2, 2023
Emerging Company Profile
Actym: programming microbes to treat solid tumors
Backed by Boehringer Ingelheim and Panacea, Actym is engineering microbes to enable safe, systemic delivery
BioCentury | Apr 27, 2023
Finance
April 27 Finance Quick Takes: Therini raises $36M A for fibrin-targeted therapies
Plus: Zura raises $80M, adds bifunctional asset in Lilly deal and updates from Foresite Diagnostics, Adcentrx, Pattern, Antiva and Mezzion
Items per page:
1 - 10 of 54